Please wait a minute...
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2006, Vol. 7 Issue (12): 8-    DOI: 10.1631/jzus.2006.B0987
    
A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial
FAN Yu-jing, CHEN Shu-jie, YU Ying-cong, SI Jian-min, LIU Bin
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China; Department of Gastroenterology, Tongren Hospital, Capital Medical University, Beijing 100730, China
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Objective: To evaluate the efficacy and safety of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules in treatment of irritable bowel syndrome. Methods: Eighty-five patients [male 32, female 53; age (45.31±11.72) years] were given live combined Bifidobacterium, Lactobacillus and Enterococcus capsules 1260 mg/d t.i.d.×4 weeks. Syndrome scales were used to evaluate the efficacy in gastrointestinal syndrome. Fecal flora was also measured before and after the treatment. Six bacteria were cultured and the colony forming units were counted in stool. SPSS was used for data analysis. Results: Seventy-four patients finished the follow-up. No side-effect was found. For treatment of irritable bowel syndrome, the effective rate of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules was 56.8% in the second week, 74.3% in the fourth week and 73.0% in the sixth week. Single symptom was improved, especially in abdominal pain and stool character. The probiotica containing live combined Bifidobacterium, Lactobacillus and Enterococcus could increase bifidobacterium count (P<0.01) and lactobacillus count (P<0.05); decrease bacteroides count (P<0.05) and enterococci count (P<0.01); No obvious changes were observed in clostridium difficile colonitis and enterobacteriaceae (P>0.05). Conclusion: The result of the study indicated that the administration of live combined Bifidobacterium, Lactobacillus and Enterococcus improved the symptom of irritable bowel syndrome and that there was a gradual increase of this effect. Thereafter conditions remained stable for 2 weeks. That improvement may be associated with alterations in gastrointestinal flora.

Key wordsIrritable bowel syndrome (IBS)      Intestinal flora      Probiotic agents     
Received: 16 March 2006     
CLC:  R574.4  
Cite this article:

FAN Yu-jing, CHEN Shu-jie, YU Ying-cong, SI Jian-min, LIU Bin. A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2006, 7(12): 8-.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.2006.B0987     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2006/V7/I12/8

[1] Liang Liu, Qi-fan Xiao, Yan-li Zhang, Shu-kun Yao. A cross-sectional study of irritable bowel syndrome in nurses in China: prevalence and associated psychological and lifestyle factors[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(6): 590-597.
[2] Liang Liu, Bei-ni Liu, Shuo Chen, Miao Wang, Yang Liu, Yan-li Zhang, Shu-kun Yao. Visceral and somatic hypersensitivity, autonomic cardiovascular dysfunction and low-grade inflammation in a subset of irritable bowel syndrome patients[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(10): 907-914.